Sabril (Vigabatrin) 500 Mg Sachets

—

Anticipated · Australia

Anticipated · 🇦🇺 Australia

Anticipated shortage

Reading today’s signals…

• Can I substitute?

No pathway on record

prescriber decision required

⇄ Best alternative

None listed

refer to prescriber

◷ Expected back

No estimate

No estimate provided

Product attributes reference data we hold

Active ingredient (INN)	Sabril (Vigabatrin) 500 Mg Sachets
Therapeutic category	Auto-created by Health Canada — Recalls and Safety Alerts scraper
Controlled substance	No

Summary of product characteristics (SPC)	Not on file

Trade price 🇦🇺 Australia · awaiting price ingest

🇦🇺 AU

Ex-manufacturer

—

Dispensed (DPMQ)

—

Pack

—

Not yet captured for Australia

Official pricing isn’t on file for this market yet. PBS (Australia), NHS Drug Tariff (United Kingdom) and CMS NADAC (United States) feeds are prioritised; this panel populates automatically once the data lands.

Substitution pathways 🇦🇺 Australia · TGA

—

No substitution instrument in force

Dispense per normal rules, or refer to the prescriber. No active SSSI/S19A instrument detected for this medicine.

Shortage status by regulator official notices

🇦🇺

Australia

TGA Recalls · 3mo ago

High

Recalls official enforcement reports

🇨🇦

Sabril (vigabatrin) 500 mg sachets

Communications and Public Affairs Branch · Nov 2023

Class ?details ↗

Verified timeline regulator events

🇦🇺 14 July 2023

high reported

Sources official regulators

🇦🇺

TGA Recalls

verified 3mo ago

verify ↗

Mederti Drug Report

Generated 3 July 2026 · Australia market · 1 regulatory source

For health-professional reference only. Mederti aggregates shortage and substitution information from official regulatory sources. It is not clinical advice and data may be incomplete or delayed. Confirm any substitution or supply decision against the primary regulator source, the prescriber, and current clinical references (e.g. AMH) before acting. Terms.